Hagop Kantarjian

Summary

Affiliation: The University of Texas
Country: USA

Publications

  1. doi request reprint Ruxolitinib for myelofibrosis--an update of its clinical effects
    Hagop M Kantarjian
    University of Texas MD Anderson Cancer Center, Houston, TX Electronic address
    Clin Lymphoma Myeloma Leuk 13:638-45. 2013
  2. pmc Results of inotuzumab ozogamicin, a CD22 monoclonal antibody, in refractory and relapsed acute lymphocytic leukemia
    Hagop Kantarjian
    Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Cancer 119:2728-36. 2013
  3. pmc Current practices in the management of chronic myeloid leukemia
    Hagop M Kantarjian
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Clin Lymphoma Myeloma Leuk 13:48-54. 2013
  4. doi request reprint Oral sapacitabine for the treatment of acute myeloid leukaemia in elderly patients: a randomised phase 2 study
    Hagop Kantarjian
    The University of Texas MD Anderson Cancer Center, Houston, TX, USA
    Lancet Oncol 13:1096-104. 2012
  5. pmc Very long-term follow-up results of imatinib mesylate therapy in chronic phase chronic myeloid leukemia after failure of interferon alpha therapy
    Hagop Kantarjian
    Leukemia Department, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 118:3116-22. 2012
  6. doi request reprint Monoclonal antibodies in adult acute lymphoblastic leukemia
    Hagop Kantarjian
    Leukemia Department, The University of Texas, MD Anderson Cancer Center, 1515 Holcombe Blvd, Unit 428, Houston, TX 77030, USA
    Hematology 17:S52-4. 2012
  7. doi request reprint Inotuzumab ozogamicin, an anti-CD22-calecheamicin conjugate, for refractory and relapsed acute lymphocytic leukaemia: a phase 2 study
    Hagop Kantarjian
    Department of Leukemia, MD Anderson Cancer Center, Houston, TX 77030, USA
    Lancet Oncol 13:403-11. 2012
  8. doi request reprint Phase I/II multicenter study to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of AZD4877 in patients with refractory acute myeloid leukemia
    H M Kantarjian
    University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Box 428, Houston, TX 77030 1402, USA
    Invest New Drugs 30:1107-15. 2012
  9. pmc Improved survival in chronic myeloid leukemia since the introduction of imatinib therapy: a single-institution historical experience
    Hagop Kantarjian
    Department of Leukemia, M D Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
    Blood 119:1981-7. 2012
  10. doi request reprint Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION)
    Hagop M Kantarjian
    The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
    Blood 119:1123-9. 2012

Detail Information

Publications191 found, 100 shown here

  1. doi request reprint Ruxolitinib for myelofibrosis--an update of its clinical effects
    Hagop M Kantarjian
    University of Texas MD Anderson Cancer Center, Houston, TX Electronic address
    Clin Lymphoma Myeloma Leuk 13:638-45. 2013
    ..The 2-year follow-up data from the COMFORT trials suggest that patients with intermediate-2 or high-risk MF receiving ruxolitinib therapy may have improved survival compared with those receiving no (placebo) or traditional therapy. ..
  2. pmc Results of inotuzumab ozogamicin, a CD22 monoclonal antibody, in refractory and relapsed acute lymphocytic leukemia
    Hagop Kantarjian
    Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Cancer 119:2728-36. 2013
    ..CD22 expression occurs in >90% of patients with acute lymphocytic leukemia (ALL). Inotuzumab ozogamicin, a CD22 monoclonal antibody bound to calicheamicin, is active in ALL...
  3. pmc Current practices in the management of chronic myeloid leukemia
    Hagop M Kantarjian
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Clin Lymphoma Myeloma Leuk 13:48-54. 2013
    ..To assess these new guidelines, a cross-sectional survey of US hematologists and/or oncologists was conducted in December 2010 through an online survey...
  4. doi request reprint Oral sapacitabine for the treatment of acute myeloid leukaemia in elderly patients: a randomised phase 2 study
    Hagop Kantarjian
    The University of Texas MD Anderson Cancer Center, Houston, TX, USA
    Lancet Oncol 13:1096-104. 2012
    ..We assessed the efficacy and toxicity of sapacitabine, a novel oral cytosine nucleoside analogue, in elderly patients with AML...
  5. pmc Very long-term follow-up results of imatinib mesylate therapy in chronic phase chronic myeloid leukemia after failure of interferon alpha therapy
    Hagop Kantarjian
    Leukemia Department, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 118:3116-22. 2012
    ..The long-term outcome of patients with chronic phase chronic myeloid leukemia treated with imatinib after failure of interferon alpha therapy has not been detailed...
  6. doi request reprint Monoclonal antibodies in adult acute lymphoblastic leukemia
    Hagop Kantarjian
    Leukemia Department, The University of Texas, MD Anderson Cancer Center, 1515 Holcombe Blvd, Unit 428, Houston, TX 77030, USA
    Hematology 17:S52-4. 2012
    ..Monoclonal antibodies targeting surface markers in acute lymphocytic leukemia (CD19, CD20 and CD22) are showing promising results and are reviewed...
  7. doi request reprint Inotuzumab ozogamicin, an anti-CD22-calecheamicin conjugate, for refractory and relapsed acute lymphocytic leukaemia: a phase 2 study
    Hagop Kantarjian
    Department of Leukemia, MD Anderson Cancer Center, Houston, TX 77030, USA
    Lancet Oncol 13:403-11. 2012
    ..CD22 is highly expressed in patients with ALL. Inotuzumab ozogamicin is a CD22 monoclonal antibody conjugated to the toxin calecheamicin. We did a phase 2 study to assess the efficacy of this antibody...
  8. doi request reprint Phase I/II multicenter study to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of AZD4877 in patients with refractory acute myeloid leukemia
    H M Kantarjian
    University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Box 428, Houston, TX 77030 1402, USA
    Invest New Drugs 30:1107-15. 2012
    ..Evidence of monoasters in all but the 4 mg/day dose group provided proof of mechanism for AZD4877. This study was terminated due to lack of efficacy. (ClinicalTrials.gov identifier NCT00486265)...
  9. pmc Improved survival in chronic myeloid leukemia since the introduction of imatinib therapy: a single-institution historical experience
    Hagop Kantarjian
    Department of Leukemia, M D Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
    Blood 119:1981-7. 2012
    ..Imatinib therapy minimized the impact of known prognostic factors and Sokal risk in CP-CML and accentuated the impact of age in AP- and BP-CML...
  10. doi request reprint Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION)
    Hagop M Kantarjian
    The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
    Blood 119:1123-9. 2012
    ..Overall, dasatinib continues to show faster and deeper responses compared with imatinib, supporting first-line use of dasatinib in patients with newly diagnosed CML-CP. This study was registered at ClinicalTrials.gov: NCT00481247...
  11. pmc Structural effects of clinically observed mutations in JAK2 exons 13-15: comparison with V617F and exon 12 mutations
    Tai Sung Lee
    Biomedical Informatics and Computational Biology, and Department of Chemistry, University of Minnesota, 207 Pleasant Street, S E, Minneapolis, MN 55455, USA
    BMC Struct Biol 9:58. 2009
    ....
  12. pmc Significant association between polymorphism of the erythropoietin gene promoter and myelodysplastic syndrome
    Wanlong Ma
    Department of Hematology Oncology, Quest Diagnostics Nichols Institute, San Juan Capistrano, CA, USA
    BMC Med Genet 11:163. 2010
    ..The G/G genotype of the single-nucleotide polymorphism (SNP) rs1617640 in the erythropoietin (EPO) promoter has been shown to be associated with decreased EPO expression. We examined the association of rs1617640 genotype with MDS...
  13. ncbi request reprint Survival advantage with imatinib mesylate therapy in chronic-phase chronic myelogenous ;eukemia (CML-CP) after IFN-alpha failure and in late CML-CP, comparison with historical controls
    Hagop Kantarjian
    Department of Leukemia, University of Texas M D Anderson Cancer Center, Houston, Texas, USA
    Clin Cancer Res 10:68-75. 2004
    ..Multivariate analyses were conducted to assess the independent prognostic effect of therapy (imatinib versus other) on survival...
  14. ncbi request reprint Imatinib mesylate therapy improves survival in patients with newly diagnosed Philadelphia chromosome-positive chronic myelogenous leukemia in the chronic phase: comparison with historic data
    Hagop M Kantarjian
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 98:2636-42. 2003
    ..This was most likely because approximately 90% of patients receiving IFN-alpha plus ara-C changed to imatinib therapy after a median of 8 months into therapy...
  15. ncbi request reprint Effects of age on prognosis with imatinib mesylate therapy for patients with Philadelphia chromosome-positive chronic myelogenous leukemia
    Jorge Cortes
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 98:1105-13. 2003
    ....
  16. ncbi request reprint High-dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome-positive chronic phase chronic myeloid leukemia
    Hagop Kantarjian
    Department of Leukemia, The University of Texas, M D Anderson Cancer Center, Houston, TX 77030, USA
    Blood 103:2873-8. 2004
    ..In conclusion, high-dose imatinib induced higher rates of complete cytogenetic response and of molecular response in patients with newly diagnosed chronic phase CML...
  17. doi request reprint Therapeutic advances in leukemia and myelodysplastic syndrome over the past 40 years
    Hagop Kantarjian
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, Texas, USA
    Cancer 113:1933-52. 2008
    ..In patients with MDS, it was recently demonstrated that epigenetic therapy with hypomethylating agents improved survival. Much therapeutic progress has been witnessed in leukemia and MDS, and much more is expected to occur soon...
  18. ncbi request reprint Results of decitabine (5-aza-2'deoxycytidine) therapy in 130 patients with chronic myelogenous leukemia
    Hagop M Kantarjian
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 98:522-8. 2003
    ..Decitabine is a hypomethylating agent that has shown encouraging preliminary anti-CML activity. This study evaluated the activity and toxicity of decitabine in different phases of CML...
  19. ncbi request reprint Cytogenetic and molecular responses and outcome in chronic myelogenous leukemia: need for new response definitions?
    Hagop Kantarjian
    Department of Leukemia, The University of Texas MD Anderson Cancer, Houston, Texas 77030, USA
    Cancer 112:837-45. 2008
    ..Response rates in chronic myeloid leukemia (CML) are now reported based on the cumulative incidence of a single-time best response. The study aim was to examine the significance of different response criteria for CML on imatinib therapy...
  20. ncbi request reprint Chronic myelogenous leukemia: a review and update of therapeutic strategies
    Guillermo Garcia-Manero
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, Texas
    Cancer 98:437-57. 2003
  21. doi request reprint Phase 3 study of dasatinib 140 mg once daily versus 70 mg twice daily in patients with chronic myeloid leukemia in accelerated phase resistant or intolerant to imatinib: 15-month median follow-up
    Hagop Kantarjian
    M D Anderson Cancer Center, Houston, TX 77030 1402, USA
    Blood 113:6322-9. 2009
    ..001). These results demonstrate that dasatinib 140 mg once daily has similar efficacy to dasatinib 70 mg twice daily but with an improved safety profile. This trial is registered at www.clinicaltrials.gov as #CA180-035...
  22. ncbi request reprint Quantitative polymerase chain reaction monitoring of BCR-ABL during therapy with imatinib mesylate (STI571; gleevec) in chronic-phase chronic myelogenous leukemia
    Hagop M Kantarjian
    Departments of Leukemia, M D Anderson Cancer Center, Houston, Texas 77030, USA
    Clin Cancer Res 9:160-6. 2003
    ..The purpose of our investigation was to evaluate the response and minimal residual disease by quantitative competitive PCR (QC-PCR) studies in patients with chronic myeloid leukemia (CML) treated with imatinib mesylate...
  23. ncbi request reprint Complete cytogenetic and molecular responses to interferon-alpha-based therapy for chronic myelogenous leukemia are associated with excellent long-term prognosis
    Hagop M Kantarjian
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 97:1033-41. 2003
    ....
  24. ncbi request reprint Phase I clinical and pharmacology study of clofarabine in patients with solid and hematologic cancers
    Hagop M Kantarjian
    Departments of Leukemia, Experimental Therapeutics, and Breast and Head and Neck, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    J Clin Oncol 21:1167-73. 2003
    ..Encouraging activity was observed in acute leukemia...
  25. ncbi request reprint Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia after failure of first-line imatinib: a randomized phase 2 trial
    Hagop Kantarjian
    Department of Leukemia, University of Texas M D Anderson Cancer Center, Houston, TX 77230 1402, USA
    Blood 109:5143-50. 2007
    ..Dasatinib represents a safe and effective therapy for CP-CML resistant to conventional imatinib doses with improved cytogenetic and molecular response rates and progression-free survival relative to high-dose imatinib...
  26. ncbi request reprint Prediction of initial cytogenetic response for subsequent major and complete cytogenetic response to imatinib mesylate therapy in patients with Philadelphia chromosome-positive chronic myelogenous leukemia
    Hagop Kantarjian
    Department of Leukemia, University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 97:2225-8. 2003
    ..Because early allogeneic stem cell transplantation (SCT) may be associated with a better outcome, early parameters predicting for subsequent cytogenetic responses would optimize the treatment decision-making...
  27. ncbi request reprint Phase 2 clinical and pharmacologic study of clofarabine in patients with refractory or relapsed acute leukemia
    Hagop Kantarjian
    Department of Leukemia, Anderson Cancer Center, Houston, TX, USA
    Blood 102:2379-86. 2003
    ..03). This increased only in responders (median, 1.8-fold; P =.008) after the second clofarabine infusion. In summary, clofarabine is active in acute leukemias and MDS; cellular pharmacokinetics may have prognostic significance...
  28. ncbi request reprint Sudden onset of the blastic phase of chronic myelogenous leukemia: patterns and implications
    Hagop Kantarjian
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 98:81-5. 2003
    ..Delaying SCT until the disease demonstrates resistance to other strategies (e.g., imatinib mesylate or interferon-alpha) entails the risk of the development of a sudden blastic phase, which may not permit enough time to perform a SCT...
  29. ncbi request reprint Long-term survival benefit and improved complete cytogenetic and molecular response rates with imatinib mesylate in Philadelphia chromosome-positive chronic-phase chronic myeloid leukemia after failure of interferon-alpha
    Hagop M Kantarjian
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston 77030, USA
    Blood 104:1979-88. 2004
    ..0001); the survival advantage was confirmed by multivariate analysis (hazard ratio, 0.19; P <.0001)...
  30. ncbi request reprint Monitoring the response and course of chronic myeloid leukemia in the modern era of BCR-ABL tyrosine kinase inhibitors: practical advice on the use and interpretation of monitoring methods
    Hagop Kantarjian
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Blood 111:1774-80. 2008
  31. ncbi request reprint Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia
    Hagop Kantarjian
    Department of Leukemia, MD Anderson Cancer Center, 1515 Holcombe Blvd, Box 428, Houston, TX 77030, USA
    Blood 109:52-7. 2007
    ..We conclude that a low-dose, dose-intensity schedule of decitabine optimizes epigenetic modulation and clinical responses in MDS...
  32. ncbi request reprint New insights into the pathophysiology of chronic myeloid leukemia and imatinib resistance
    Hagop M Kantarjian
    Department of Leukemia, MD Anderson Cancer Center, Houston, Texas 77030, USA
    Ann Intern Med 145:913-23. 2006
    ....
  33. ncbi request reprint Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL
    Hagop Kantarjian
    Department of Leukemia, University of Texas M D Anderson Cancer Center, Houston, TX 77230 1402, USA
    N Engl J Med 354:2542-51. 2006
    ..Preclinical in vitro studies have shown that nilotinib (AMN107), a new BCR-ABL tyrosine kinase inhibitor, is more potent than imatinib against CML cells by a factor of 20 to 50...
  34. ncbi request reprint New strategies in chronic myeloid leukemia
    Hagop M Kantarjian
    Department of Leukemia, The University of Texas, M D Anderson Cancer Center, Houston, Texas 77030, USA
    Int J Hematol 83:289-93. 2006
    ..Further clinical trials are needed to characterize the efficacy and safety profile of these new agents and to determine which agents improve the long-term prognosis for patients with CML who have shown resistance to imatinib...
  35. ncbi request reprint Survival benefit with imatinib mesylate versus interferon-alpha-based regimens in newly diagnosed chronic-phase chronic myelogenous leukemia
    Hagop M Kantarjian
    Department of Leukemia, Unit 428, The University of Texas M D Anderson Cancer Center, PO Box 301402, Houston, TX 77230 1402, USA
    Blood 108:1835-40. 2006
    ....
  36. pmc Survival advantage with decitabine versus intensive chemotherapy in patients with higher risk myelodysplastic syndrome: comparison with historical experience
    Hagop M Kantarjian
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 109:1133-7. 2007
    ..The comparative efficacy of these 2 forms of treatment in MDS is unknown. The objective of the current study was to compare the efficacy and toxicity profiles of decitabine and intensive chemotherapy in MDS...
  37. ncbi request reprint Important therapeutic targets in chronic myelogenous leukemia
    Hagop M Kantarjian
    The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Clin Cancer Res 13:1089-97. 2007
    ..Review the state-of-art knowledge of the biology and therapy of chronic myelogenous leukemia (CML)...
  38. ncbi request reprint Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study
    Hagop Kantarjian
    Department of Leukemia, University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 106:1794-803. 2006
    ..Decitabine indirectly depletes methylcytosine and causes hypomethylation of target gene promoters...
  39. ncbi request reprint Long-term follow-up results of the combination of topotecan and cytarabine and other intensive chemotherapy regimens in myelodysplastic syndrome
    Hagop Kantarjian
    Department of Leukemia, University of Texas M D Anderson Cancer Center, Houston, Texas 77230, USA
    Cancer 106:1099-109. 2006
    ..Topotecan-cytarabine regimens have shown encouraging results in higher-risk MDS. The aim of this study was to analyze the long-term results with topotecan-cytarabine versus other intensive chemotherapy regimens in higher-risk MDS...
  40. ncbi request reprint Results of intensive chemotherapy in 998 patients age 65 years or older with acute myeloid leukemia or high-risk myelodysplastic syndrome: predictive prognostic models for outcome
    Hagop Kantarjian
    Department of Leukemia, University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 106:1090-8. 2006
    ....
  41. ncbi request reprint Outcome of patients with Philadelphia chromosome-positive chronic myelogenous leukemia post-imatinib mesylate failure
    Hagop Kantarjian
    Department of Leukemia, University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 109:1556-60. 2007
    ..The prognosis of patients with chronic myelogenous leukemia (CML) after failure of imatinib mesylate therapy is not well documented...
  42. ncbi request reprint The incidence and impact of thrombocytopenia in myelodysplastic syndromes
    Hagop Kantarjian
    Department of Leukemia, University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 109:1705-14. 2007
    ..Many approved and investigational MDS therapies caused or exacerbated preexisting thrombocytopenia. The incidence of severe bleeding in MDS was greater than reported in current guidelines...
  43. ncbi request reprint The degree of bone marrow fibrosis in chronic myelogenous leukemia is not a prognostic factor with imatinib mesylate therapy
    Hagop M Kantarjian
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Leuk Lymphoma 46:993-7. 2005
    ..88%; P = 0.27) and failure-free survival rates (69 vs. 77%; P = 0.34) were also not different. We conclude that the previously established poor prognostic significance of marrow fibrosis in CML is less relevant with imatinib therapy...
  44. ncbi request reprint Decitabine dosing schedules
    Hagop M Kantarjian
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Semin Hematol 42:S17-22. 2005
    ..Even with all the information we have learned, there is still a need to determine the optimal dosing schedule and the development of alternative dosing forms...
  45. ncbi request reprint Significance of myelofibrosis in early chronic-phase, chronic myelogenous leukemia on imatinib mesylate therapy
    Hagop M Kantarjian
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 104:777-80. 2005
    ..Myelofibrosis is associated historically with a poor prognosis in patients with chronic myelogenous leukemia (CML). Its significance in the recent era of effective therapy with imatinib mesylate is unknown...
  46. ncbi request reprint Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance
    Hagop M Kantarjian
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, TX 77230 1402, USA
    Blood 110:3540-6. 2007
    ..In summary, nilotinib is highly active and safe in patients with CML-CP after imatinib failure or intolerance. This clinical trial is registered at http://clinicaltrials.gov as ID no. NCT00109707...
  47. ncbi request reprint Clofarabine: past, present, and future
    Hagop M Kantarjian
    Department of Leukemia, The University of Texas M D Andreson Cancer Center, Houston, Texas 77030, USA
    Leuk Lymphoma 48:1922-30. 2007
    ..Ongoing and future studies will examine the use of clofarabine in elderly patients with AML for whom standard regimens are too toxic, and in MDS intravenous and oral forms of the drug...
  48. ncbi request reprint Update of the decitabine experience in higher risk myelodysplastic syndrome and analysis of prognostic factors associated with outcome
    Hagop M Kantarjian
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 109:265-73. 2007
    ..In this study, the authors update their experience with decitabine in patients with MDS and analyze the cytogenetic response patterns and prognostic factors associated with decitabine therapy...
  49. ncbi request reprint Therapeutic choices in younger patients with chronic myelogenous leukemia
    H M Kantarjian
    Department of Leukemia, M D Anderson Cancer Center, Houston, Texas, USA
    Cancer 89:1647-58. 2000
    ..Both therapies may be suitable for younger patients. The authors reviewed current data to assist in prioritizing these modalities in an individual patient...
  50. ncbi request reprint Response to therapy is independently associated with survival prolongation in chronic myelogenous leukemia in the blastic phase
    H M Kantarjian
    Department of Leukemia, M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 92:2501-7. 2001
    ..The association of treatment response with survival was evaluated by multivariate and landmark analyses...
  51. ncbi request reprint Homoharringtonine: history, current research, and future direction
    H M Kantarjian
    Department of Leukemia, M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 92:1591-605. 2001
    ..Cephalotoxine esters, including homoharringtonine (HHT), have shown encouraging activity in leukemia in initial studies in China and in later studies in the U.S...
  52. ncbi request reprint Homoharringtonine and low-dose cytarabine in the management of late chronic-phase chronic myelogenous leukemia
    H M Kantarjian
    Departments of Leukemia, Bioimmunotherapy, Biostatistics, and Blood and Bone Marrow Transplantation, M D Anderson Cancer Center, Houston, TX 77030, USA
    J Clin Oncol 18:3513-21. 2000
    ....
  53. doi request reprint Phase II study of clofarabine monotherapy in previously untreated older adults with acute myeloid leukemia and unfavorable prognostic factors
    Hagop M Kantarjian
    University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    J Clin Oncol 28:549-55. 2010
    ..This phase II study assessed clofarabine monotherapy in older adults (>or= 60 years of age) with untreated acute myeloid leukemia (AML) and at least one unfavorable baseline prognostic factor...
  54. doi request reprint Safety and efficacy of romiplostim in patients with lower-risk myelodysplastic syndrome and thrombocytopenia
    Hagop Kantarjian
    Leukemia Department, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Box 428, Houston, TX 77030, USA
    J Clin Oncol 28:437-44. 2010
    ..To assess the safety and efficacy of romiplostim, a peptibody that increases platelet production, for treatment of thrombocytopenic patients with myelodysplastic syndromes (MDS)...
  55. ncbi request reprint Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia
    Hagop Kantarjian
    M D Anderson Cancer Center, Houston, TX 77030, USA
    N Engl J Med 346:645-52. 2002
    ..Chronic myelogenous leukemia (CML) is caused by the BCR-ABL tyrosine kinase, the product of the Philadelphia chromosome. Imatinib mesylate, formerly STI571, is a selective inhibitor of this kinase...
  56. pmc Phase I clinical and pharmacokinetic study of oral sapacitabine in patients with acute leukemia and myelodysplastic syndrome
    Hagop Kantarjian
    The University of Texas M D Anderson Cancer Center, Department of Leukemia, Unit 428, 1515 Holcombe Blvd, Houston, TX 77030, USA
    J Clin Oncol 28:285-91. 2010
    ..Sapacitabine is an oral deoxycytidine nucleoside analog with a unique mechanism of action that is different from cytarabine...
  57. ncbi request reprint Imatinib mesylate (STI571) therapy for Philadelphia chromosome-positive chronic myelogenous leukemia in blast phase
    Hagop M Kantarjian
    Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Blood 99:3547-53. 2002
    ..04), and lower 4-week induction mortality (4% versus 15%, P =.07). Imatinib mesylate is currently being tested in combination with other drugs to improve the prognosis for blast-phase CML...
  58. doi request reprint Outcome of adults with acute lymphocytic leukemia in second or subsequent complete remission
    Hagop M Kantarjian
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Leuk Lymphoma 51:475-80. 2010
    ..These results could be used in assessing the efficacy of new treatments aimed at improving CR durations and survival post salvage therapy...
  59. pmc Phase 2 study of romiplostim in patients with low- or intermediate-risk myelodysplastic syndrome receiving azacitidine therapy
    Hagop M Kantarjian
    Leukemia Department, University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Blood 116:3163-70. 2010
    ..0035) compared with placebo. Grade 3 rash and arthralgia each were reported in 1 romiplostim-treated patient (4%). This study suggests romiplostim may provide clinical benefits in MDS patients during azacitidine therapy...
  60. doi request reprint Intensive chemotherapy does not benefit most older patients (age 70 years or older) with acute myeloid leukemia
    Hagop Kantarjian
    Department of Leukemia, University of Texas M D Anderson Cancer Center, Houston, TX, USA
    Blood 116:4422-9. 2010
    ..In summary, the prognosis of most patients (72%) ≥ 70 years of age with AML is poor with intensive chemotherapy (8-week mortality ≥ 30%; median survival < 6 months)...
  61. ncbi request reprint Adult acute lymphocytic leukemia. Introduction and questions related to current programs
    H M Kantarjian
    Department of Leukemia, University of Texas M D Anderson Cancer Center, Houston, Texas, USA
    Hematol Oncol Clin North Am 14:1205-8, VII. 2000
    ..This article lists some of the questions related to the current treatment programs for ALL and notes the remaining articles in this issue that address those questions...
  62. doi request reprint Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial
    Hagop M Kantarjian
    The University of Texas, MD Anderson Cancer Center, Leukemia Department, Houston, TX 77030, USA
    Lancet Oncol 12:841-51. 2011
    ..We present data from the Evaluating Nilotinib Efficacy and Safety in clinical Trials-newly diagnosed patients (ENESTnd) study after a minimum follow-up of 24 months...
  63. doi request reprint Impact of treatment end point definitions on perceived differences in long-term outcome with tyrosine kinase inhibitor therapy in chronic myeloid leukemia
    Hagop Kantarjian
    The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Unit 428, Houston, TX 77030, USA
    J Clin Oncol 29:3173-8. 2011
    ..Different definitions of progression-free survival (PFS) and event-free survival (EFS) may result in perceived differences in outcomes with tyrosine kinase inhibitor (TKI) therapies in chronic myelogenous leukemia (CML)...
  64. doi request reprint Proposal for a new risk model in myelodysplastic syndrome that accounts for events not considered in the original International Prognostic Scoring System
    Hagop Kantarjian
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 113:1351-61. 2008
    ....
  65. ncbi request reprint Adult acute lymphocytic leukemia. Future research directions
    H M Kantarjian
    Department of Leukemia, University of Texas M D Anderson Cancer Center, Houston, Texas, USA
    Hematol Oncol Clin North Am 15:207-11, viii. 2001
    ..This new research includes dose intensive anthracyclines, novel agents, STI571 for Philadelphia chromosome-positive ALL, and risk-oriented strategies...
  66. doi request reprint Second-generation tyrosine kinase inhibitors: the future of frontline CML therapy
    Hagop M Kantarjian
    The University of Texas, M D Anderson Cancer Center, Houston, Texas 77030, USA
    Clin Cancer Res 17:1674-83. 2011
    ..Future CML therapy might include earlier use of these agents to help more patients achieve complete molecular response and may be a path to a CML cure...
  67. doi request reprint Nilotinib is effective in patients with chronic myeloid leukemia in chronic phase after imatinib resistance or intolerance: 24-month follow-up results
    Hagop M Kantarjian
    The University of Texas M D Anderson Cancer Center, Leukemia Department, 1515 Holcombe Blvd, Houston, TX 77030, USA
    Blood 117:1141-5. 2011
    ..This study indicates that nilotinib is effective, with a manageable safety profile, and can provide favorable long-term benefits for patients with CML-CP after imatinib failure...
  68. doi request reprint Defining the course and prognosis of adults with acute lymphocytic leukemia in first salvage after induction failure or short first remission duration
    Hagop M Kantarjian
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 116:5568-74. 2010
    ..The objectives of this study were to define the prognosis for adult patients with ALL after first salvage through multivariate analyses of patient and disease characteristics...
  69. doi request reprint Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia resistant to imatinib at a dose of 400 to 600 milligrams daily: two-year follow-up of a randomized phase 2 study (START-R)
    Hagop Kantarjian
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, Texas 77230 1402, USA
    Cancer 115:4136-47. 2009
    ..Data with a minimum of 2 years of follow-up were available for the current study of dasatinib and high-dose imatinib in CP-CML resistant to imatinib at daily doses from 400 mg to 600 mg...
  70. ncbi request reprint Treatment of philadelphia chromosome-positive, accelerated-phase chronic myelogenous leukemia with imatinib mesylate
    Hagop M Kantarjian
    Departments of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Clin Cancer Res 8:2167-76. 2002
    ..Imatinib mesylate, a specific Bcr-Abl tyrosine kinase inhibitor, has shown encouraging activity in chronic myelogenous leukemia (CML)...
  71. doi request reprint Efficacy of imatinib dose escalation in patients with chronic myeloid leukemia in chronic phase
    Hagop M Kantarjian
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 115:551-60. 2009
    ..Treatment guidelines propose dose escalation based on clinical assessments of disease response...
  72. ncbi request reprint Imatinib mesylate for Philadelphia chromosome-positive, chronic-phase myeloid leukemia after failure of interferon-alpha: follow-up results
    Hagop M Kantarjian
    Departments of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Clin Cancer Res 8:2177-87. 2002
    ..We identified pretreatment and treatment-associated factors that were associated with higher major cytogenetic response rates and with improved survival...
  73. pmc Significance of increasing levels of minimal residual disease in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in complete cytogenetic response
    Hagop M Kantarjian
    Department of Leukemia, The University of Texas, M D Anderson Cancer Center, 1515 Holcombe Blvd, Unit 428, Houston, TX 77030, USA
    J Clin Oncol 27:3659-63. 2009
    ..The clinical significance of increasing levels of QPCR in patients in CGCR is uncertain...
  74. ncbi request reprint Imatinib mesylate therapy for relapse after allogeneic stem cell transplantation for chronic myelogenous leukemia
    Hagop M Kantarjian
    Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston 77030, USA
    Blood 100:1590-5. 2002
    ..We conclude that imatinib mesylate effectively controlled CML that recurred after allogeneic SCT, but it was associated with side effects including myelosuppression and recurrence of severe GVHD...
  75. doi request reprint Secondary myelodysplastic syndrome in a patient with Philadelphia-positive acute lymphoblastic leukemia after achieving a major molecular response with hyperCVAD plus imatinib mesylate
    Arturo Vega-Ruiz
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Leuk Res 32:1468-71. 2008
    ..The patient then developed myelodysplastic syndrome and solitary central nervous system relapse of ALL...
  76. doi request reprint Current and future management options for myelodysplastic syndromes
    Jeffrey Bryan
    Department of Leukemia, The University of Texas, M D Anderson Cancer Center, Houston, Texas 77030, USA
    Drugs 70:1381-94. 2010
    ..This review focuses on supportive care modalities, the approved agents indicated for the treatment of MDS and future directions for the treatment of MDS, including agents under clinical investigation...
  77. ncbi request reprint Mylotarg combined with topotecan and cytarabine in patients with refractory acute myelogenous leukemia
    Jorge Cortes
    Department of Leukemia, The University of Texas, M D Anderson Cancer Center, 1400 Holcombe Boulevard, Houston, Texas 77030, USA
    Cancer Chemother Pharmacol 50:497-500. 2002
    ..Topotecan and cytarabine (ara-C) is an effective anti-AML regimen. A pilot study of Mylotarg combined with topotecan and ara-C (MTA) was conducted in patients with refractory AML...
  78. ncbi request reprint Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia
    Deborah A Thomas
    Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, 77230, USA
    Cancer 106:1569-80. 2006
    ..Prognosis of BL and B-ALL has been poor with conventional NHL or ALL regimens, but has improved with dose-intensive regimens...
  79. doi request reprint Phase 2 trial of rituximab plus hyper-CVAD alternating with rituximab plus methotrexate-cytarabine for relapsed or refractory aggressive mantle cell lymphoma
    Michael Wang
    Department of Lymphoma and Myeloma, The University of Texas M D Anderson Cancer Center, Houston, Texas, USA
    Cancer 113:2734-41. 2008
    ....
  80. doi request reprint Delayed achievement of cytogenetic and molecular response is associated with increased risk of progression among patients with chronic myeloid leukemia in early chronic phase receiving high-dose or standard-dose imatinib therapy
    Alfonso Quintas-Cardama
    Departments of Leukemia, University of Texas M D Anderson Cancer Center, Houston, 77030, USA
    Blood 113:6315-21. 2009
    ..This risk is discernible as early as 3 months into imatinib therapy by molecular analysis and may provide the rationale to institute therapies that render higher rates of early response...
  81. ncbi request reprint Clinical relevance of vascular endothelial growth factor receptors 1 and 2 in acute myeloid leukaemia and myelodysplastic syndrome
    Srdan Verstovsek
    Department of Leukemia, The University of Texas, M D Anderson Cancer Center, Houston, TX 77030, USA
    Br J Haematol 118:151-6. 2002
    ..These data suggest that VEGF expression, rather than the expression of its receptors, is the determining factor in the biological behaviour of AML and MDS, and that VEGFRs are differentially expressed in AML and MDS...
  82. ncbi request reprint Gemtuzumab ozogamicin, fludarabine, cytarabine and cyclosporine combination regimen in patients with CD33+ primary resistant or relapsed acute myeloid leukemia
    Apostolia Tsimberidou
    Department of Leukemia, The University of Texas, M D Anderson Cancer Center, 1515 Holcombe Blvd, Unit 428, Houston, TX 77030, USA
    Leuk Res 27:893-7. 2003
    ..CSA inclusion in gemtuzumab ozogamicin-based regimens is feasible. MFAC is an effective regimen for refractory AML...
  83. ncbi request reprint Phase I/II study of subcutaneous homoharringtonine in patients with chronic myeloid leukemia who have failed prior therapy
    Alfonso Quintas-Cardama
    Department of Leukemia, University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 109:248-55. 2007
    ..Homoharringtonine (HHT) is a cephalotaxus alkaloid that inhibits the synthesis of proteins leading to apoptosis. Intravenous HHT has demonstrated activity in patients with chronic myeloid leukemia (CML) after failure with interferon...
  84. ncbi request reprint Differences in CD33 intensity between various myeloid neoplasms
    Iman Jilani
    Department of Hematopathology, University of Texas M D Anderson Cancer Center, Houston 77030, USA
    Am J Clin Pathol 118:560-6. 2002
    ..There was no correlation between CD33 intensity and response to therapy or overall survival in 35 patients treated with protocols including Mylotarg. These data demonstrate variation in CD33 intensity between various leukemias...
  85. ncbi request reprint Clinical activity of farnesyl transferase inhibitors in hematologic malignancies: possible mechanisms of action
    Elias Jabbour
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Leuk Lymphoma 45:2187-95. 2004
    ..Ongoing studies will better determine their mechanism of action and the role of combination with other agents, defining their place in the therapeutic arsenal of hematologic disorders...
  86. ncbi request reprint Pilot study of gemtuzumab ozogamicin, liposomal daunorubicin, cytarabine and cyclosporine regimen in patients with refractory acute myelogenous leukemia
    Efrosyni Apostolidou
    Department of Leukemia, M D Anderson Cancer Center, University of Texas, Box 428, 1515 Holcombe Blvd, Houston, TX 77030, USA
    Leuk Res 27:887-91. 2003
    ..The inclusion of CSA in a gemtuzumab ozogamicin-containing regimen is feasible. The MDAC regimen was associated with significant toxicity in a cohort of patients with very advanced AML...
  87. ncbi request reprint Sudden blastic transformation in patients with chronic myeloid leukemia treated with imatinib mesylate
    Elias Jabbour
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Blood 107:480-2. 2006
    ..SBT is still a rare event, probably less common than that observed with IFN-alpha therapy. Continuous monitoring of patients treated with imatinib is mandatory...
  88. ncbi request reprint Phase I study of cloretazine (VNP40101M), a novel sulfonylhydrazine alkylating agent, combined with cytarabine in patients with refractory leukemia
    Francis Giles
    Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, 77030, USA
    Clin Cancer Res 11:7817-24. 2005
    ..A phase I study of cloretazine combined with cytarabine (1-beta-d-arabinofuranosylcytosine, ara-C) was conducted in patients with refractory disease...
  89. ncbi request reprint A phase I study of intravenous LBH589, a novel cinnamic hydroxamic acid analogue histone deacetylase inhibitor, in patients with refractory hematologic malignancies
    Francis Giles
    Department of Leukemia, University of Texas M D Anderson Cancer Center, Houston, 77030, USA
    Clin Cancer Res 12:4628-35. 2006
    ..LBH589 is a novel histone deacetylase inhibitor that inhibits proliferation and induces apoptosis in tumor cell lines. In this phase I study, LBH589 was administered i.v. as a 30-minute infusion on days 1 to 7 of a 21-day cycle...
  90. ncbi request reprint Clinical relevance of VEGF receptors 1 and 2 in patients with chronic myelogenous leukemia
    Srdan Verstovsek
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, P O Box 428, Houston, TX 77030, USA
    Leuk Res 27:661-9. 2003
    ..In contrast, high VEGF-R1 levels did not correlate with a specific CML phase, characteristic, or outcome. Our findings support VEGF-R2 over-expression as an independent prognostic indicator for shortened survival in patients with CML...
  91. ncbi request reprint Use of arsenic trioxide (As2O3) in the treatment of patients with acute promyelocytic leukemia: the M. D. Anderson experience
    Guillermo Lazo
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 97:2218-24. 2003
    ..It has been reported that arsenic trioxide (As(2)O(3)) is effective in this setting. The authors report the experience of The M. D. Anderson Cancer Center with As(2)O(3) in the treatment of patients with recurrent APL...
  92. ncbi request reprint Biphenotypic acute leukaemia: a case series
    Ahmed Aribi
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston TX 77030, USA
    Br J Haematol 138:213-6. 2007
    ..Seven patients were treated with regimens designed for AML. Complete remission (CR) rates of 78% and 57% were noted respectively. The overall survival probability at 2 years was 60%...
  93. ncbi request reprint Chronic myelogenous leukemia in T cell lymphoid blastic phase achieving durable complete cytogenetic and molecular remission with imatinib mesylate (STI571; Gleevec) therapy
    Ehab Atallah
    Department of Leukemia, University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 94:2996-9. 2002
    ..Standard therapy for such patients is undetermined. Imatinib mesylate, a Bcr-Abl tyrosine kinase inhibitor, has shown activity in CML...
  94. ncbi request reprint Optimal first-line treatment of chronic myeloid leukemia. How to use imatinib and what role for newer drugs?
    Elias Jabbour
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Oncology (Williston Park) 21:653-62; discussion 663-4, 667-8. 2007
    ..Combination strategies are currently being investigated in preliminary clinical studies and may prove to be useful. Overall, there are an increasing number of treatment options now available for patients with CML...
  95. doi request reprint Dynamic model for predicting death within 12 months in patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis
    Constantine S Tam
    Leukemia Department, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
    J Clin Oncol 27:5587-93. 2009
    ..We aimed to define an accelerated phase (AP) in MF by characterizing disease features that can identify patients with median overall survival of <or= 12 months at any time in the disease course...
  96. pmc Phase 2 and pharmacodynamic study of oral forodesine in patients with advanced, fludarabine-treated chronic lymphocytic leukemia
    Kumudha Balakrishnan
    Department of Experimental Therapeutics, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Blood 116:886-92. 2010
    ..Forodesine has biologic activity in CLL; pharmacodynamic parameters suggest that an alternate dosing schedule and/or higher doses to achieve greater intracellular dGTP may be beneficial in this patient population...
  97. ncbi request reprint Response of idiopathic hypereosinophilic syndrome to treatment with imatinib mesylate
    Patricia Ault
    Department of Leukemia, M D Anderson Cancer Center, University of Texas, 1515 Holcombe Boulevard, Box 428, Houston, TX 77030, USA
    Leuk Res 26:881-4. 2002
    ..The possible mechanism of response is discussed. This observation may lead to a better understanding of the pathophysiology of HES, and may provide a new form of effective therapy for the disease...
  98. ncbi request reprint T-cell large granular lymphocytic (T-LGL) leukemia: experience in a single institution over 8 years
    Ahmed Aribi
    Department of Leukemia, Unit 428, University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Leuk Res 31:939-45. 2007
    ..Significant responses were not seen with any of these treatment regimens. We conclude that cyclosporine therapy may be beneficial for T-LGL leukemia patients. New treatment modalities are needed for these patients...
  99. ncbi request reprint Management of patients with systemic mastocytosis: review of M. D. Anderson Cancer Center experience
    Bryan Hennessy
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Am J Hematol 77:209-14. 2004
    ..SM is rare and has no effective standard of care. Collaboration among academic centers to accrue enough patients to evaluate novel therapeutic strategies is needed...
  100. ncbi request reprint Pilot study of Mylotarg, idarubicin and cytarabine combination regimen in patients with primary resistant or relapsed acute myeloid leukemia
    Yesid Alvarado
    Department of Leukemia, The University of Texas, M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, Texas, 77030, USA
    Cancer Chemother Pharmacol 51:87-90. 2003
    ..A combination of an anthracycline and cytarabine (ara-C) is the core of most AML induction regimens. We conducted a pilot study of Mylotarg combined with idarubicin and ara-C in patients with refractory or relapsed AML...
  101. doi request reprint Quantifying the survival benefit for allogeneic hematopoietic stem cell transplantation in relapsed acute myelogenous leukemia
    Paul M Armistead
    Department of Stem Cell Transplantation and Cellular Therapy, MD Anderson Cancer Center, Houston Texas, USA
    Biol Blood Marrow Transplant 15:1431-8. 2009
    ..Our data suggest that HSCT is preferable to chemotherapy alone in these patients with poor prognoses, with particular benefits noted in patients under age 50 years...